Literature DB >> 8614869

Osteosarcoma after chemotherapy for neuroblastoma.

V M Kriss1, C B Stelling.   

Abstract

Entities:  

Mesh:

Year:  1995        PMID: 8614869     DOI: 10.1007/bf00204869

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


× No keyword cloud information.
  13 in total

Review 1.  Advances in childhood solid tumors.

Authors:  L F Sinks; T Sumer
Journal:  Adv Pediatr       Date:  1978

Review 2.  Malignancies associated with immunosuppressive or cytotoxic therapy.

Authors:  I Penn
Journal:  Surgery       Date:  1978-05       Impact factor: 3.982

3.  Second primary neoplasms in children.

Authors:  M Tefft; G F Vawter; A Mitus
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1968-08

4.  Radionuclide skeletal survey for pediatric neoplasms.

Authors:  D L Gilday; J M Ash; B J Reilly
Journal:  Radiology       Date:  1977-05       Impact factor: 11.105

5.  Second malignancies associated with chemotherapeutic agents.

Authors:  R A Kyle
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

Review 6.  Malignancy as a complication of immunosuppressive therapy.

Authors:  S Leibowitz; R S Schwartz
Journal:  Adv Intern Med       Date:  1971

7.  CT of AIDS-related lymphoma.

Authors:  R R Townsend
Journal:  AJR Am J Roentgenol       Date:  1991-05       Impact factor: 3.959

8.  Bladder cancer following administration of cyclophosphamide.

Authors:  C Durkee; R Benson
Journal:  Urology       Date:  1980-08       Impact factor: 2.649

Review 9.  Pediatric HIV infection: an imaging update.

Authors:  J O Haller; H L Cohen
Journal:  Pediatr Radiol       Date:  1994

Review 10.  Drug-induced cancer.

Authors:  R Hoover; J F Fraumeni
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

View more
  1 in total

1.  Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice.

Authors:  Susie Lee; Lawrence A Donehower; Alan J Herron; David D Moore; Loning Fu
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.